A 2026 study in Hepatology Communications examines what happens when two diabetes medicines are combined - a GLP-1 receptor agonist and an SGLT2 inhibitor - in people with MASLD and type 2 diabetes, with liver fibrosis progression as the outcome of interest. The study matters because each drug class has already shown a liver signal on its own, and the natural next question is whether the two together do more than either alone.
The two classes work through different doors. A GLP-1 receptor agonist acts on appetite and insulin, driving weight loss and metabolic improvement. An SGLT2 inhibitor makes the kidneys excrete more glucose, and it appears to have a direct liver effect that runs separately from weight loss - a finding this site covered when it looked at dapagliflozin. Combining them is the field’s way of asking whether the two doors open onto the same liver from different directions.
Why the combination question matters
The reason to combine rather than escalate is that fibrosis is the outcome that actually changes a person’s future, and neither class has a large, settled fibrosis win on its own yet. A combination that moves fibrosis more than either alone would be a genuine step, and a combination that simply adds side effects without adding benefit would be a cautionary tale. The study sits at exactly that fork, which is why it earns a careful read rather than a headline.
The honest boundary is that this is a study of an existing combination in a specific population - MASLD with type 2 diabetes - not a new approval. The medicines are prescribed for diabetes, and their liver effects are a signal being worked out, not a settled indication a reader should seek on their own.
Where the plate still fits
Drug-combination stories are exactly where the database earns its keep, because the medicines do not replace the plate - they change the context around it. A GLP-1 agonist suppresses appetite, which means the food a person does eat has to work harder; an SGLT2 inhibitor changes glucose handling, which means the quality of the carbohydrate matters more. The Recommended column is the pattern that holds up under both.
The specific numbers keep it concrete. Lean proteins like chicken breast and fish anchor the plate during weight loss on these medicines; legumes and whole grains bring fiber and steady carbohydrate; olive oil and walnuts carry the unsaturated fat. Salmon sits around 1.3 grams of saturated fat per 100 grams with omega-3s, and rolled oats carry about 10 grams of fiber per 100 grams. These are the foods that pair with the two drugs rather than fight them.
How our editorial team read this
We read combination studies with a standing rule: never let the excitement of two drugs inflate a signal into an indication. Our data editor verified the study, the classes, and the population, and kept every claim at the level the authors themselves use - a signal being worked out, not a settled fibrosis win. We did not present the combination as something a reader should request, and we did not frame the diet as a substitute for prescribed diabetes care.
What we did do is keep the food guidance inside its lane. The medicines are a clinician’s decision, the plate is the daily lever, and the study is one more data point in how the two interact. The reader-facing line is that the Recommended column becomes more important on these medicines, not less.
The practical takeaway
For someone with MASLD and type 2 diabetes, the combination study is a reason to keep both tools sharp: the prescription under a clinician’s watch, and the Recommended column under the reader’s own control. The database covers the plate; the doctor covers the medicines; the liver reads the combination of both.